Drug Development Considerations for the Prevention of Healthcare Associated Infections

The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are co-sponsoring this public virtual workshop on August 30, 2022. All meeting materials—including agenda, panelist affiliations/disclosures, speaker slides, workshop recording, and transcript—will be posted here shortly before and/or after the completion of the workshop.

• The current state of development of pathogen-directed products used to prevent healthcare-associated infections (HAIs).
• Evidence supporting decolonization and pathogen reduction (in colonized patients) as a strategy to prevent infection and transmission of antimicrobial-resistant healthcare-associated pathogens.
• Antimicrobial resistance threats as potential targets for decolonization and pathogen reduction.
• Challenges and potential approaches to drug development and registration of products for the prevention of healthcare-associated infections.

This meeting will be held in virtual format only. Registration is required for online attendance and will be available until 12 p.m. EDT on August 29, 2022.